Latest pharmaceutical news #pharma #code


Posted On May 19 2017 by

#latest pharmaceutical news

#

Product

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu.

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo.

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape.

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po.

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programm.

Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage sm.

Scientists at Florida Atlantic University’s Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale’s coast contains.

Diabetes heightens the risk of vascular damage to heart and limbs, and impairs the ability to repair damage with new growth of blood vessels, called angiogenesis. There a.

A type of sugar found naturally in some women’s breast milk may protect new born babies from infection with a potentially life threatening bacterium called Group B strept.

A team including the National Cancer Center (NCC) (Tokyo, Japan), the RIKEN Center for Life Science Technologies (CLST) (Yokohama, Japan), and Carna Biosciences Inc. (Kob.

An international team of researchers – led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni.

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical inve.





Last Updated on: May 19th, 2017 at 10:45 am, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *